Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Cbr2em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Cbr2em1flox/Cya

Common Name
Cbr2-flox
Product ID
S-CKO-18239
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-12409-Cbr2-B6J-VB
Status
Research and Development
When using this mouse strain in a publication, please cite “Cbr2-flox Mouse (Catalog S-CKO-18239) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Cbr2-flox
Strain ID
CKOCMP-12409-Cbr2-B6J-VB
Gene Name
Cbr2
Product ID
S-CKO-18239
Gene Alias
MLCR
Background
C57BL/6JCya
Gene Full Name
carbonyl reductase 2
Modification
Conditional knockout
NCBI ID
12409 (Mouse)
Phenotype
MGI:107200
Chromosome
Chr 11 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000026148
NCBI Transcript ID
NM_007621
Target Region
Exon 2~8
Size of Effective Region
~2.6 kb
Overview of Gene Research
Cbr2, also known as NADH-Cytochrome B5 reductase 2, is involved in multiple biological processes. It has been implicated in angiogenesis and is related to the endocannabinoid system through cannabinoid receptor 2 (CBR2) [1,2,3,4,5,6,7]. In the context of the endocannabinoid system, CBR2 is expressed on leukocytes and plays a role in immunosuppression and inflammation regulation [5]. In addition, in non-primate species, Cbr2 is essential for sperm-zona pellucida interaction and fertilization [8].

In the study of diabetic retinopathy, Cbr2 expression was significantly downregulated in DM rat retinas and HG-stimulated human retinal microvascular endothelial cells (HRMECs). Intravitreal injection of CBR2-expressing lentivirus reduced retinal angiogenesis, acellular capillary formation, and pericyte loss, along with decreased expression of hypoxia-inducible factor-1α (HIF-1α), cluster of differentiation 31 (CD31), and vascular endothelial growth factor A (VEGFA) in vivo. CBR2 overexpression in HG-induced HRMECs inhibited cell growth and tube formation and decreased HIF-1α and VEGFA expression. When VEGFA was overexpressed, the repressive effects of CBR2 on cell proliferation, migration, and tube formation under HG conditions were reversed, suggesting Cbr2 alleviates retinal vascular dysfunction and abnormal endothelial proliferation by regulating VEGFA [1]. In breast cancer, nuclear CBR2 was negatively correlated with grade and positively correlated with estrogen receptor and progesterone receptor-positive status. High cytoplasmic expression of CBR2 was associated with a higher locoregional and distant recurrence rate, though not statistically significant [2]. In preterm birth, the expression of CBR2 in the placenta was significantly lower in women after preterm birth compared to those after term births, indicating that decreased CBR2 expression could potentially serve as an indicator for predicting preterm birth [6].

In conclusion, Cbr2 plays important roles in various biological processes and disease conditions. In diabetic retinopathy, it may regulate retinal vascular function by modulating VEGFA. In breast cancer, its expression is associated with certain prognostic factors. In preterm birth, its reduced placental expression might be a predictive marker. The study of Cbr2 through in vivo models such as in the diabetic retinopathy research helps to understand its function in disease mechanisms, providing potential targets for disease treatment.

References:
1. Chen, Jun, Sun, Yizhou, Chen, Lei, Zhou, Yun. 2022. NADH-Cytochrome B5 reductase 2 suppresses retinal vascular dysfunction through regulation of vascular endothelial growth factor A in diabetic retinopathy. In Experimental eye research, 222, 109186. doi:10.1016/j.exer.2022.109186. https://pubmed.ncbi.nlm.nih.gov/35820466/
2. Morin-Buote, Jessica, Ennour-Idrissi, Kaoutar, Poirier, Éric, Durocher, Francine, Diorio, Caroline. 2021. Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer Patients. In Journal of personalized medicine, 11, . doi:10.3390/jpm11090852. https://pubmed.ncbi.nlm.nih.gov/34575629/
3. Santos, Ivan, P P Oliveira, M Beatriz, Casas, Ana, Fidalgo, Javier, Almeida, Hugo. 2024. Understanding the Potential of CBD for Health Benefits: an Overview. In Current drug discovery technologies, , . doi:10.2174/0115701638305553240529103622. https://pubmed.ncbi.nlm.nih.gov/38847170/
4. Casadoumecq, Ana Clara, Fernández-Solari, José Javier, Elverdin, Juan Carlos, Rodríguez, Pablo Alejandro, Mohn, Claudia Ester. 2022. The role of the endocannabinoid system in tooth eruption: An ex vivo study. In Australian endodontic journal : the journal of the Australian Society of Endodontology Inc, 49 Suppl 1, 79-88. doi:10.1111/aej.12695. https://pubmed.ncbi.nlm.nih.gov/36226979/
5. Capozzi, Antonella, Caissutti, Daniela, Mattei, Vincenzo, Manera, Clementina, Misasi, Roberta. 2021. Anti-Inflammatory Activity of a CB2 Selective Cannabinoid Receptor Agonist: Signaling and Cytokines Release in Blood Mononuclear Cells. In Molecules (Basel, Switzerland), 27, . doi:10.3390/molecules27010064. https://pubmed.ncbi.nlm.nih.gov/35011295/
6. Feduniw, Stepan, Krupa, Izabela, Łagowska, Katarzyna, Stawarz, Barbara, Raba, Grzegorz. 2024. Placental Cannabinoid Receptor Expression in Preterm Birth. In Journal of pregnancy, 2024, 6620156. doi:10.1155/2024/6620156. https://pubmed.ncbi.nlm.nih.gov/38745869/
7. Christie, Stewart, Brookes, Simon, Zagorodnyuk, Vladimir. 2021. Endocannabinoids in Bladder Sensory Mechanisms in Health and Diseases. In Frontiers in pharmacology, 12, 708989. doi:10.3389/fphar.2021.708989. https://pubmed.ncbi.nlm.nih.gov/34290614/
8. Ebert, Bettina, Kisiela, Michael, Maser, Edmund. 2014. Human DCXR - another 'moonlighting protein' involved in sugar metabolism, carbonyl detoxification, cell adhesion and male fertility? In Biological reviews of the Cambridge Philosophical Society, 90, 254-78. doi:10.1111/brv.12108. https://pubmed.ncbi.nlm.nih.gov/24720935/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research